Methods-Algorithms for calculations in the multidimensional normal distribution and procedures for Monte Carlo simulation of risk distributions were implemented in the S-PLUS programming language and used to construct programs producing risk estimates and risk distributions. Parameters of risk marker distributions and correlations were obtained from the scientific literature.
The basic operation of screening as defined by Wald 1 is a division of the screened population into one group with a low risk of being aVected and another group with a risk suYciently high to warrant further diagnostic examinations.
This division may be based on a combination of markers with diVerent distributions among aVected and unaVected people and an a priori risk defined for the individual person by biological, demographic, or social criteria.
A classic example is screening maternal serum for fetal Down's syndrome during the second trimester of pregnancy, using the biochemical markers -fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE 3 ), and the maternal age related a priori risk for giving birth to a child with Down's syndrome child. 2 The risk is calculated from the multivariate likelihood ratio distributions 3 and reported as a single number-for example, 1:450-interpreted as the risk of the woman giving birth to a child with Down's syndrome.
It has been convincingly shown that there is a close agreement between such predicted risks and the observed prevalence of Down's syndrome. 4 5 Likewise, the prospective use of screening maternal serum during the second trimester has been extensively documented in many populations 6 and found to be in very good agreement with model based predictions of screening performance. The population eVects of various screening programmes can thus be inferred from statistical models. [7] [8] [9] Recently, the risk estimates obtained through nuchal translucency screening in weeks [11] [12] [13] [14] have been shown to correspond closely to the actual risk. 10 The calculated risk for the individual woman is traditionally reported without any information about imprecision caused by analytical variation, 11 variation induced by the risk algorithm , 12 biological variation, or combinations of these. 13 14 This reflects the fact that the risk calculation from an individual laboratory is based on well known marker distributions containing both the interpersonal and analytical variation, so that the precision of the risk estimate does not depend on the composition of this variation. However, knowledge of the imprecision of an individual risk estimate, understood as the variation in risk estimates found by obtaining a new risk estimate from parameters determined once more-for example, risk estimates obtained in screening for Down's syndrome by sending the same sample twice to the laboratory-may be important for the woman when she has to decide on a reaction to the risk estimate. 12 The variation between people is not easily measured, and discrepancies between diVerent laboratories are only rarely reported, but they become apparent in quality control programmes. Furthermore, knowledge of the source and level of imprecision may enable the designer of a screening programme to improve performance 15 -for example, through the use of better assays for serum markers, more rigorous gestational dating in prenatal screening, or a recommendation of repeat testing of screen positive and borderline screen negative women. 13 Finally, the availability of simulation programs is of importance for assessment of the medical technology of diverse screening procedures.
Here we present a computer program able to perform risk calculations and estimates of precision of risk estimates in multivariate likelihood ratio based screening, and we use the program to estimate the imprecision of Down's syndrome risk estimates obtained through screening during the first trimester and the relation between the precision of the risk markers and the precision of the risk estimate. The consequence of the variation in risk estimate for the construction of quality control schemes is analysed.
Risk calculation
In multidimensional screening based on the likelihood ratio we calculate a risk of being aVected, based on the observation of a series of predefined markers (most often serological or biometric), where a given observation is known to have the probability f(observed) if the person is aVected and h(observed) if the person is unaVected. The likelihood ratio r(observed) = f(observed)/h(observed) reflects the increase in probability that the person is aVected based on the examined markers. Often the log likelihood ratio q(observed) = log10r(observed) is used as it is more likely to be symmetrical and thus conform to the normal distribution. To obtain the actual risk of being aVected the r(observed) will have to be combined with an a priori risk, a, of being aVected-for example, the age related risk for fetal Down's syndrome in Down's syndrome screening. The exact probability of a given vector of observation, f(X) with X = (x 1 ,x 2 ,x 3 , . . .,x n ) in a multidimensional normal distribution can be calculated from the known mean values of variables and their variancecovariance matrix as described elsewhere. 3 7 9 16 Estimation of precision of risk The eVect of imprecision in the determination of either of the variables in observations on the risk estimate is diYcult to calculate exactly with conventional numerical methods. However, the variation of the risk estimate may, if the errors of the variables are normally distributed (and this will normally be the case), be simulated by a Monte Carlo method using the "true" value of the observations (the mean of repeated determinations) and the dispersion matrix (variance-covariance matrix) of the variation connected with repeated measurements on the same sample, or on samples from the same woman within a short period. A Monte Carlo method 17 is a statistical simulation method where the distribution of variables is described by probability density functionsfor example, the log likelihood distributions mentioned above modified as described by the dispersion matrix of the variation-and the variation of a risk estimate is obtained by repeated random sampling from these probability density functions. The sampling is controlled by a random number generator available in the S-PLUS program. Thus, the use of Monte Carlo simulation is comparable with estimating the probability of an event-for example, heads or tails of a coin-by repeating the experiment that may lead to the event-for example, the tossing of a coin-many times instead of calculating the probability from knowledge of the two equally likely outcomes. The calculated risk, p, is very close to a/r(observed) for small values of the a priori risk a. This gives the variance of p: V(p) V(r)a 2 . It is thus possible to give good confidence intervals for the value of p, as a function of the variation of the markers and the a priori risk value. If a percentage error may be attached to the likelihood ratio r, the same percentage error may be attached to p.
Results
In figure 1 is shown the density distributions of risk estimates in two cases with risk estimates on both sides of the risk cut oV 1:400. Increasing variation of the markers causes an increase in the variation of the risk estimate, and this will lead to an increase in the proportion of risk estimates going from an average value above or below the risk cut oV to a value on the other side of the cut oV. As the number of people below the cut oV is larger than the number above, the increasing spread will lead to an increased false positive rate of the screening and-to a much lesser extent-a decrease in detection rate. Increasing marker variation may thus lead to an increased likelihood of misclassification of individual pregnancies. So, increasing the variation of markers will both increase the imprecision of the particular risk estimate and reduce the eVectiveness of screening. In figure 1 , the variability of individual variables is taken to be independent when calculating the dispersion matrix. This will not always be the case. In the case of variation caused by incorrect gestational dating, some of the marker variations will be highly correlated.
Discussion
In screening for Down's syndrome, the likelihood ratios (estimates of risk) are broadly distributed ( fig 1) and even at a low within laboratory SD of individual markers, 0.01 log MoM (CV 2.3%), the variation is considerable. This means that it is likely that the same pregnant woman would get diVerent risk estimates from being examined at diVerent departments or laboratories. The United Kingdom National External Quality Assessment Schemes (NEQAS) quality control scheme for first trimester screening for Down's syndrome 14 distributes serum samples from pregnant women and information on nuchal translucency thickness and receives risk estimates from participating laboratories. The registered ranges of the risk estimates obtained at the United Kingdom NEQAS quality control scheme for first trimester from three women (pools S002, S003, and S005) who both had nuchal translucency measured and serum analysed were from 1:1 to 1:95 (high risk case), from 1:12 to 1:350 (intermediate risk), and from 1:2400 to 1:10756 (low risk). These findings are understandable when considering the great variation induced by measurement inaccuracies. Furthermore, other causes for variation of risk estimates between laboratories have been identified-for example, diVerences in calculation of medians, diVerences in biochemical assays used, diVerences in the quality of ultrasound, and many others-so it should not come as a surprise that the risk estimate of an individual pregnant woman is associated with considerable variation between and within laboratories. The finding of total variations (biological and analytical) of the order of 20%-40% between concentrations of screening markers in serum samples from the second trimester, taken twice from the same woman, 13 corroborates that risk estimates will be highly variable.
The reported risk estimate is still the best discriminator between aVected and unaVected pregnancies, and far better than age alone as a risk marker for Down's syndrome, and as such, is a good background for decision making about diagnostic testing. Furthermore, we know that when the population of pregnant women is divided into groups based on risk estimates, then the risk estimates reflect the actual risk. 4 5 The consequence of the variabil-ity of the individual risk estimates, however, could be that in counselling pregnant women, less emphasis should be placed on the precise value of the risk estimate and more on whether she is screening positive or not, or whether she has a high or very high risk, as opposed to a low or very low risk. Both the risk estimate and its grouping within these categories should be reported, and the use of either form of result should be based on an individual assessment. To define whether a person is screen positive or not is the core activity of screening and thus the activity for which the screening procedure has been optimised. It is not the purpose of a screening programme to identify with certainty a particular aVected patient-which patient is identified is of no importance for the screening as long as the detection rate and false positive rate is unchanged.
Analytical imprecision causes variation in individual risk estimates and also influences the separation between aVected and unaVected women. The eVect on discrimination-that is, the relevance for the false positive rate and the detection rate-is contained within the distribution of marker values, and only upon changes in the variation of marker values (figure 1) can this type of change be expected. In the worst case scenario, where the distributions of markers become so broad and overlapping that they are not informative, the risk will be the a priori risk. To obtain a better estimate of the individual risk, it has been shown that screening is improved-albeit not to an extent that justifies the increased cost-if two tests are performed on the same woman 13 and particularly so, if repeat testing is oVered to screen positive and borderline screen negative women.
The findings reported here are important for the evaluation of quality control schemes, as it is evident that risk estimates are very vulnerable to variations in marker concentrations, whereas the screening overall performance is much less so. It is thus doubtful whether quality control measures should be directed towards ensuring identical risk estimates from diVerent laboratories. It seems much more relevant to require that screening laboratories continously monitor the distribution of risk estimates to detect an increasing false positive rate, and the distribution of the biochemical and biometric variables to detect variations that may aVect the screening. Ideally, a screening programme should be controlled by careful clinical follow up, but this is only rarely possible and the cost is probably only justifiable for the duration of the establishment of variables used in the risk algorithms. Alternatively, the correct classification of samples submitted for proficiency testing into screen positive and screen negative should be checked. With a low frequency of those truly aVected, as is the case for the trisomies, eVective quality control is essential.
The programs described here may help in identifying sources of variation and estimate their importance for the variation of individual risk estimates. The importance of such calculations for the total economy of screening programmes has been documented and it is clear that economic considerations put narrow limits on the allowable variance of screening markers. 19 
